Abbott Opens the Door to More Effective Biologic Treatments Through New Technology
Abbott has opened up a whole new set of possibilities for drug development and biologic treatments that have the potential to more effectively treat individuals with cancer, autoimmune diseases and other complicated conditions.
Discovered by Abbott scientists, dual-variable domain Ig (DVD-Ig™) is the first technology that combines the function and specificity of two or more monoclonal antibodies (mAbs) into one molecule that demonstrates drug-like properties and manufacturing feasibility. These DVD-Ig molecules will allow for the development of individual drug candidates that target multiple disease pathways.
Published in Nature Biotechnology, this landmark study demonstrates a completely new platform that may be relevant to a variety of therapeutic categories in which multiple disease-mediators are at play. Simultaneous blockage of multiple targets using DVD-Ig molecules may increase efficacy in comparison to inhibition of a single target using a monoclonal antibody.
Click here to read the press release.
Illustration 1
Illustration 2
Illustration 3
Illustration 4
